Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
Indian Pediatr
;
1995 Sep; 32(9): 983-8
Article
in English
| IMSEAR
| ID: sea-6401
ABSTRACT
OBJECTIVES:
To study immunogenicity and reactogenicity of indigenously produced MMR vaccine and to assess the booster effect of MMR immunization on measles seroconversion.DESIGN:
A longitudinal follow up.SETTING:
Hospital based and home follow up, as required.SUBJECTS:
89 children already immunized for measles, between 15 to 24 months of age for immunogenic evaluation and 866 subjects for the reactogenic component.METHODS:
Prevaccination and postvaccination samples collected one and four weeks after vaccination were studied by ELISA for IgG and IgM antibodies against the three diseases. A clinical follow up of immunized children was done at 3 days, 7 days, 6 weeks and 6 months after immunization.RESULTS:
IgG positivity 4 weeks after immunization rose from 75% to 100% for measles, from 12% to 92% for mumps, and from 13% to 99% for rubella. Only mild side effects including pain and swelling in 37 (4.3%) cases, mild fever in 51 (5.9%) cases, cough in 40 (4.6%) cases and a transient rash in 7 (0.8%) cases were observed.CONCLUSIONS:
The indigenously manufactured MMR vaccine has an excellent immunogenicity and low reactogenicity with a booster effect for measles seroconversion in children already immunized for this disease.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Prognosis
/
Rubella
/
Female
/
Humans
/
Male
/
Enzyme-Linked Immunosorbent Assay
/
Measles Vaccine
/
Mumps Vaccine
/
Rubella Vaccine
/
Viral Vaccines
Type of study:
Controlled clinical trial
/
Etiology study
/
Incidence study
/
Observational study
/
Prognostic study
/
Risk factors
Language:
English
Journal:
Indian Pediatr
Year:
1995
Type:
Article
Similar
MEDLINE
...
LILACS
LIS